SEC Comment Letter for NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545) (SDEV) — Apr 9, 2019
NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)
Date: April 9, 2019 · CIK: 0001389545 · Accession: 0000000000-19-006842
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-230672
Letter
April 9, 2019 Justin Hall Interim Chief Executive Officer NovaBay Pharmaceuticals, Inc. 2000 Powell Street, Suite 1150 Emeryville, CA 94608 Re:NovaBay Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed April 1, 2019 File No. 333-230672 Dear Mr. Hall: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tonya K. Aldave at (202) 551-3601 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Abby E. Brown, Esq.
Show Raw Text
April 9, 2019
Justin Hall
Interim Chief Executive Officer
NovaBay Pharmaceuticals, Inc.
2000 Powell Street, Suite 1150
Emeryville, CA 94608
Re:NovaBay Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed April 1, 2019
File No. 333-230672
Dear Mr. Hall:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tonya K. Aldave at (202) 551-3601 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Abby E. Brown, Esq.